Nasdaq:ADPT
Adaptive Biotechnologies Corp
A clinical-stage biotech firm utilizing proprietary immunoengineering technology to create personalized immunotherapies for cancer and autoimmune conditions.
Key Metrics
Investment Thesis
Bull Case
Investors may find value in Adaptive Biotechnologies due to its exclusive ownership of the world's largest human antibody dataset, which underpins a highly differentiated platform for developing personalized cancer treatments. The recent revenue growth trajectory and substantial cash on hand suggest the company has sufficient runway to advance key clinical programs toward late-stage development. Strategic partnerships with industry leaders de-risk the commercialization path and provide potential near-term milestone payments.
Bear Case
The stock carries significant downside risk given the company's persistent net losses and a negative operating profit, indicating it is still far from generating positive cash flows from its core business. Heavy dependence on a few partners exposes the firm to partnership termination risks that could abruptly cut off revenue sources. With high interest expenses eating into limited capital, the path to profitability remains uncertain without successful product launches or major new funding rounds.
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp. is a clinical-stage biotechnology company leveraging its proprietary Adaptive Immunoengineering Platform to develop next-generation immunotherapies for oncology and autoimmune diseases. Headquartered in Seattle, the company serves patients globally through strategic partnerships with major pharmaceutical entities, focusing on personalized cancer vaccines and other innovative biologics. With significant investments in research and development totaling approximately $94 million recently, the firm aims to transform how the immune system is understood and engineered to fight disease.
Analysis
Management Discussion
Despite a significant net loss of $59.5 million in the most recent year, the company successfully grew its revenue to $277 million, representing a substantial increase from prior years. The balance sheet remains robust with cash and equivalents totaling $70.5 million, providing a cushion against operating burn and interest obligations. However, the negative operating profit and high general and administrative expenses highlight the ongoing challenges in scaling operations before achieving sustainable commercialization.
Industry Overview
The biotechnology and immunotherapy sector is experiencing rapid growth driven by advancements in precision medicine and an increasing focus on personalized cancer treatments. Companies in this space are competing fiercely for approval of novel therapies that can improve patient outcomes while navigating complex regulatory landscapes. Success in this industry requires substantial capital investment in R&D and the ability to navigate long clinical trial timelines to bring products to market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $185.3M | $170.3M | $179.0M | $277.0M |
| Cost of Revenue | $57.9M | $75.6M | $72.1M | $71.4M |
| Gross Profit | $127.4M | $94.7M | $106.9M | $205.6M |
| Operating Expenses | $327.6M | $321.8M | $269.4M | $262.7M |
| Operating Income | $-200.2M | $-227.0M | $-162.5M | $-57.1M |
| R&D | $141.8M | $122.1M | $103.0M | $93.8M |
| G&A | $88.5M | $83.9M | $72.8M | $72.7M |
| Marketing | $95.6M | $88.6M | $84.8M | $94.6M |
| Stock-Based Comp | $55.5M | $62.9M | $53.6M | $51.5M |
| D&A | — | — | $19.3M | $16.0M |
| Depreciation | $19.2M | $20.5M | $17.6M | $16.1M |
| Amortization | $1.7M | $1.7M | $1.7M | $1.7M |
| Other OpEx | $1.7M | $27.1M | $8.9M | $1.7M |
| Non-Operating Income | $-182.0K | $1.7M | $3.0M | $-2.3M |
| Interest Expense | $4.2M | $13.8M | $11.6M | $11.8M |
| Pre-Tax Income | $-200.4M | $-225.3M | $-159.6M | $-59.5M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-200.4M | $-225.3M | $-159.6M | $-59.5M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-200.4M | $-225.3M | $-159.6M | $-59.5M |
| Minority Interest | $-177.0K | $-54.0K | $-103.0K | $42.0K |
| Net to Common | $-200.2M | $-225.2M | $-159.5M | $-59.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $562.1M | $410.2M | $283.8M | $300.2M |
| Cash & Equivalents | $90.0M | $65.1M | $47.9M | $70.5M |
| Accounts Receivable | $40.1M | $38.0M | $41.7M | $50.4M |
| Inventory | $14.5M | $14.4M | $8.4M | $9.8M |
| Prepaid Expenses | $9.4M | $11.4M | $11.3M | $13.0M |
| Other Current Assets | $408.2M | $281.3M | $174.4M | $156.5M |
| Long-Term Assets | $294.5M | $250.9M | $255.6M | $212.6M |
| PP&E (Net) | $83.4M | $68.2M | $48.6M | $34.1M |
| Goodwill | $119.0M | $119.0M | $119.0M | $119.0M |
| Operating Leases | $80.8M | $52.1M | $45.8M | $40.6M |
| Other LT Assets | $11.3M | $11.7M | $42.3M | $18.9M |
| Total Assets | $856.6M | $661.1M | $539.4M | $512.7M |
| Current Liabilities | $109.8M | $88.0M | $98.1M | $89.9M |
| Accounts Payable | $8.1M | $7.7M | $7.3M | $6.5M |
| Current Debt | — | — | $865.0K | $4.6M |
| Current Leases | $9.2M | $9.4M | $10.2M | $8.9M |
| Deferred Revenue | $64.1M | $48.6M | $55.7M | $45.2M |
| Taxes Payable | $194.0K | $59.0K | $176.0K | $541.0K |
| Other Current Liab | $15.7M | $13.6M | $15.7M | $16.5M |
| Long-Term Liabilities | $282.7M | $264.8M | $238.8M | $197.8M |
| Long-Term Debt | — | $130.7M | $132.4M | $126.6M |
| LT Operating Leases | $98.8M | $89.4M | $79.1M | $70.2M |
| Other LT Liab | $125.4M | $0 | $20.0K | $20.0K |
| Total Liabilities | $392.5M | $352.9M | $336.9M | $287.7M |
| Shareholders' Equity | $464.1M | $308.3M | $202.5M | $225.0M |
| Paid-In Capital | $1.39B | $1.45B | $1.51B | $1.58B |
| Retained Earnings | $-919.1M | $-1.14B | $-1.30B | $-1.36B |
| AOCI | $-4.1M | $215.0K | $166.0K | $253.0K |
| Total L&E | $856.6M | $661.1M | $539.4M | $512.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-200.4M | $-225.3M | $-159.6M | $-59.5M |
| Non-Cash Adjustments | $47.7M | $100.9M | $75.9M | $38.3M |
| Working Capital Changes | $-31.3M | $-31.9M | $-11.5M | $-24.8M |
| Cash from Operations | $-183.9M | $-156.3M | $-95.2M | $-46.0M |
| Capital Expenditures | $16.3M | $10.7M | $3.7M | $3.0M |
| Cash from Investing | $2.9M | $129.6M | $77.8M | $38.0M |
| Cash from Financing | $132.3M | $2.2M | $241.0K | $30.4M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-48.8M | $-24.4M | $-17.2M | $22.4M |
| Beginning Cash | $141.2M | $92.4M | $68.0M | $50.8M |
| Ending Cash | $92.4M | $68.0M | $50.8M | $73.2M |
Frequently Asked Questions
How does Adaptive Biotechnologies Corp make money?
The company's revenue primarily stems from collaborations with large pharmaceutical partners to develop and license its Adaptive Immunoengineering Platform. Key segments include oncology-focused therapeutic candidates, such as personalized cancer vaccines, and broader applications in autoimmune diseases. Additionally, revenue is generated through intellectual property licensing and milestone payments associated with these strategic partnerships.
What are the main risks for ADPT?
The company faces substantial risk from its heavy reliance on a limited number of strategic partners who control the majority of its revenue streams. Continued net losses and a large retained earnings deficit indicate that profitability is not yet achieved, creating pressure to monetize assets quickly. Regulatory approval timelines for novel immunotherapies are uncertain and can vary significantly, potentially delaying commercialization. High levels of long-term debt and interest expenses could strain liquidity if cash flow from operations does not improve.
What is ADPT's competitive advantage?
The company possesses a unique proprietary platform that enables the rapid engineering of immune cells to target specific tumor antigens with high precision. Its extensive data repository of human antibody sequences provides a deep understanding of the immune system, creating a significant barrier to entry for competitors. Strong cash reserves and efficient working capital management relative to peers allow for continued R&D investment despite current losses.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.